Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs IDEXX Laboratories, Inc. — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.79 (market cap $2.98B), while IDEXX Laboratories, Inc. trades at $516.73 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 13.6× MicroSectors FANG and Innovation 3X Leveraged ETN's market cap, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| FNGU | IDXX | |
|---|---|---|
Market Cap | $2.98B | $40.43B |
Volume | 4,682,352 | 692,164 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $766.68 |
52-Week Low | $13.73 | $504.70 |
Typical Hold Time | 19 Days | 46 Days |
Enterprise Value | — | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $36.62, down 1.56% today. Technical indicators show a bullish trend with strong moving average support, though oscillators remain neutral. The ETN provides triple exposure to tech giants like Nvidia, Meta, and Apple, but carries significant volatility risks as highlighted by recent analysis showing an 87% decline during previous tech sector downturns.
The outlook remains highly speculative given the leveraged structure. While bullish technicals suggest potential upside if tech stocks continue performing, the extreme volatility and historical drawdowns present substantial risk. Investors should weigh the amplified returns against the possibility of rapid losses during market corrections.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
